“It is quite an honor to be included on the Inc. 5000 list for the second year in arow. It is a testament to our many happy patients, who continue to recommend us to their friends and family year after year!”, says Donaldson.

COLUMBUS, Ohio (PRWEB)
September 12, 2019

Donaldson Plastic Surgery & Aesthetic Solutions has been recognized on both a local and national scale in two recent and well-renowned listing publications, the Inc. 5000 and Columbus’s Fast 50, highlighting the practice among the country’s fastest-growing privately held businesses for the 2019 year.

Dr. Jeffrey Donaldson, CEO and owner of Donaldson Plastic Surgery & Aesthetic Solutions, is excited and proud to be featured in these respected publications for the growth the practice has seen under his leadership. This is the second consecutive year that Donaldson Plastic Surgery has made both lists, and the third year overall that they have made the Fast 50 list.

Inc. 5000

Inc. magazine revealed that Donaldson Plastic Surgery & Aesthetic Solutions is No. 3861 on its annual Inc. 5000 list. Ranking higher than last year, the practice is one of 5000 companies nationwide that were selected for growth achieved in a three-year period. The 2019 Inc. 5000 list is ranked according to percentage revenue growth when comparing 2015 and 2018.

The list represents a unique look at the most successful companies within the American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“It is quite an honor to be included on the Inc. 5000 list for the second year in a row. It is a testament to our many happy patients, who continue to recommend us to their friends and family year after year!”, says Donaldson.

Not only have the companies on the 2019 Inc. 5000 been very competitive within their markets, but the list as a whole shows staggering growth compared with prior lists. The 2019 Inc. 5000 achieved an astounding three-year average growth of 454 percent, and a median rate of 157 percent. The Inc. 5000’s aggregate revenue was $237.7 billion in 2018, accounting for 1,216,308 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000.

Fast 50

Columbus Business First recently honored Donaldson Plastic Surgery & Aesthetic Solutions with a position on its 24th Annual Fast 50 list, a collection of central Ohio companies that have seen the largest average annual revenue growth over the past three years.

Making the list first in 2013, then again in 2018, Donaldson Plastic Surgery was only the fifth medical practice ever to be honored, and the first plastic surgery practice ever to appear, in the Fast 50.

“Our staff is thrilled to be named among the Fast 50, Columbus’s fastest-growing companies, for the third time. We all work very hard to create the finest plastic surgical and aesthetic experiences in central Ohio, and our consistent growth is one important measure of these efforts.”, Donaldson says.

Rankings of the 50 honorees will be revealed at the Columbus Business First awards luncheon at the Hilton Columbus Downtown on Oct. 22, 2019. You can view the entire 2019 list on the Columbus Business First website.

About Donaldson Plastic Surgery & Aesthetic Solutions

Since 2008, Donaldson Plastic Surgery has been helping Columbus residents look and feel their best through personalized surgical and nonsurgical procedures. Dr. Jeffrey Donaldson is a board-certified plastic surgeon and member of the American Society of Plastic Surgeons with more than a decade of training and experience. He is an expert in aesthetic surgery, specializing in body contouring, breast procedures, and nonsurgical facial rejuvenation.

2019 has been a big year for the Columbus practice. They celebrated entering their second decade, welcomed a second plastic surgeon, and, due to their rapid growth and a need for expansion, moved offices. They are now located in the bustling Bridge Park community, adjacent to Historic Dublin, in Columbus, Ohio. Their new office occupies a 7,030 square foot space, with a 615 square foot balcony, above the Avenue Steakhouse.

To learn more about Donaldson Plastic Surgery and the services they offer, or to schedule a consultation, visit their website at donaldsonplasticsurgery.com, call the office at 614-442-7610, or follow them on social media @donaldsonplasticsurgery.

Share article on social media or email:

DALLAS (PRWEB)
September 12, 2019

The Prelude Network (Prelude) announces today that Christine Mansfield, M.D. has joined the award-winning reproductive endocrinology team as Medical Director at its Dallas Aspire Fertility practice. Prior to her new role, Dr. Mansfield served as Medical Director at Aspire’s partner network clinic, Arizona Reproductive Institute, in Tucson. Her specialty areas include fertility preservation, in-vitro fertilization (IVF) and treating patients with diminished ovarian reserve.

Dr. Mansfield received her medical degree from the University of Alabama School of Medicine and completed her obstetrics/gynecology residency at the University of Alabama Hospital System in Birmingham. She completed a three-year fellowship in reproductive endocrinology and infertility at the University of Texas Southwestern Medical School. Dr. Mansfield is currently a member of the American College of Obstetricians and Gynecologists, American Society of Reproductive Medicine and the Society of Reproductive Endocrinology & Infertility. Committed to providing compassionate care that is personalized to every patient, Dr. Mansfield considers patient care a team effort that involves advanced technology coupled with expert care.

“I am honored to join a team of renowned professionals who have dedicated their careers to helping patients realize their dreams of having their own families,” says Dr. Mansfield. “Aspire Fertility has earned the strong reputation of providing patients with compassionate, personalized care and I am excited to be part of a mission that is an important component of the fertility journey.”

Aspire Fertility is shifting the paradigm of fertility treatment by raising the standard of care, streamlining care into an integrated system, and enhancing the overall patient experience. Now part of the Prelude Network, Aspire Fertility brings together the top medical and scientific minds in the industry with the goal of providing the very best outcomes possible for their patients. Dr. Christine Mansfield will work alongside reproductive endocrinologist, Dr. Linda Elkins, who serves as IVF Director for Aspire Fertility in Dallas. Dr. Elkins is also a clinical instructor of Obstetrics and Gynecology at the Methodist Hospital Dallas.

Along with Dr. Mansfield, Dr. John Wu has also joined the practice at Aspire Fertility in Dallas. Board certified in Obstetrics and Gynecology, Dr. Wu earned his medical degree from Texas A&M College of Medicine with honors. He completed his residency in Obstetrics and Gynecology at the world-renowned Johns Hopkins Hospital, where he won awards for resident education. He completed his fellowship in Reproductive Endocrinology and Infertility at the University of Texas at Southwestern.

“The additions of Dr. Mansfield and Dr. Wu to our team of renowned experts furthers our commitment to provide patients with only the highest level of service and care that will help them in welcoming a healthy baby to their families,” says TJ Farnsworth, Founder and CEO of Inception, the parent company to the Prelude Network. “Dr. Mansfield’s experiences as both a reproductive endocrinologist and leader in the fertility industry will make a great impact on our practice, as well as the lives of our patients.”

To learn more about Aspire Fertility, please visit https://www.aspirefertility.com/dallas-texas.

About Inception

Inception was founded in 2015 with an ambitious goal to create a family of organizations intent on improving the way patients experience their fertility journey. The company’s mission is to shift the paradigm of the fertility market by raising the standard of care, streamlining fragmented components into an integrated system, and enhancing the overall patient experience. Inception’s network of full service fertility centers, The Prelude Network, is now the largest of its kind including some of the country’s top-tier fertility practices in 17 markets across the US.

http://www.inceptionllc.com / http://www.aspirefertility.com

Share article on social media or email:

“We are glad that AWS is joining iPatientCare as a Grand Sponsor of NUCON 2019 and looking forward to their offerings and demonstrations providing more learning opportunities at NUCON 2019.” said Shripal Shah, Senior Technology Officer, iPatientCare/AssureCare

CINCINNATI (PRWEB)
September 12, 2019

iPatientCare, a pioneer in cloud-based ambulatory EHR, revenue cycle management services, integrated practice management, and patient engagement solutions, announced today the participation of Amazon Web Services (AWS) as a Grand Sponsor at National User Conference (NUCON) 2019. The annual conference features informative sessions about upcoming enhancements, user’s wish-lists based discussion sessions, hands-on demos with iPatientCare experts and exhibition showcasing the leading-edge technologies.

AWS is one of the world’s most comprehensive and broadly adapted cloud providers. It offers more than 100 fully-featured services trusted by millions of active customers around the world, including some of the fastest-growing start-ups, largest enterprises, and leading government agencies – to power their infrastructure, making them more agile, and lower costs.

This year’s annual user conference would focus on proposed enhancements in iPatientCare technology that deliver context-sensitive pro-active guidelines for practicing value-based care. The knowledge sharing will be continued with a discussion on topics relating to value-based care, MACRA/MIPS, PCMH, telehealth/remote patient monitoring, and specialty-focused implementations.

“iPatientCare is privileged to have Amazon Web Services as one of their Sponsors/Exhibitors at iPatientCare – NUCON 2019. Their participation in NUCON 2018 last year was very fruitful for all attendees and led to some of our most successful user engagements. We are glad that AWS is joining iPatientCare as a Grand Sponsor of NUCON 2019 and looking forward to their offerings and demonstrations providing more learning opportunities, and to help the attendees to maximize their time spent at NUCON 2019.” said Shripal Shah, Senior Technology Officer, iPatientCare/AssureCare

About iPatientCare

iPatientCare is a full suite of innovative healthcare products and value-added services that help physician offices, rural health clinics, and community/federally qualified health centers (CHC/FQHC) nationwide in improving the health of their patients, enhancing patient care through care management/coordination/analytics, and reducing costs of care delivery.

The awards-winning EHR, integrated practice solutions and value-added services, such as, the revenue cycle enhancement and quality improvement consulting, provide everything you need to control your practice operations, increase revenues, and provide better patient care.

iPatientCare helps healthcare providers to dramatically reduce A/R days and improve collections rates, reduce billing costs, eliminate the burden of repeatable, high volume work on their internal teams, and plug gaps in staffing and internal bandwidth. The revenue cycle teams are comprised of senior executives with extensive experience in clinically-driven revenue cycle management systems including certified billers and coders with managerial capabilities to facilitate client interactions, escalations and SLA.

The iPatientCare EHR 18.0, has received 2015 Edition ONC Health IT certification by Drummond Group, an Office of the National Coordinator-Authorized Certification Body (ONC-ACB), in accordance with the applicable eligible professional certification criteria adopted by the Secretary of Health and Human Services (HHS). Full certification details can be found at the ONC Certified Health IT Product List.

As part of its MACRA-ready solutions, iPatientCare has been recognized as a qualified MACRA-MIPS registry by CMS, and has a distinguished credit of being selected as a preferred EHR and medical billing software by more than 70,000 users nationwide, numerous hospitals/health systems, federally funded regional extension centers, and in the past by the US Army and NASA Space Medicine.

Visit https://ipatientcare.com for more information.

Share article on social media or email:

St. Joseph’s Hospital patient tower expansion team celebrated the project’s topping out on Sept. 10.

“We look forward to completing this exciting addition, ensuring BayCare and St. Joseph’s Hospital continues to provide superior healthcare services to the Tampa community.”

TAMPA, Fla. (PRWEB)
September 13, 2019

St. Joseph’s Hospital, Robins & Morton, HOK Architecture, Carastro Engineering and honored guests joined together to celebrate the structural topping out of the St. Joseph’s Hospital patient tower expansion located in Tampa, Florida, on Sept. 10.

The expansion project will include a new six-story patient tower that will house a two-story lobby, waiting and on-call rooms and three patient care floors with 90 private patient rooms. A new bridge will connect St. Joseph’s Hospital to St. Joseph’s Women’s Hospital, allowing for patient transport from one facility to the other.

“Robins & Morton is proud to partner with BayCare and St. Joseph’s Hospital on this exciting project,” Robins & Morton Senior Superintendent Steve Williams said. “The scope of this project connects St. Joseph’s Hospital, St. Joseph’s Children’s Hospital and St. Joseph’s Women’s Hospital, providing safe and efficient pedestrian paths between all three facilities. We look forward to completing this exciting addition, ensuring BayCare and St. Joseph’s Hospital continues to provide superior healthcare services to the Tampa community.”

The patient tower expansion is scheduled to be completed in mid-2020.

About Robins & Morton

Robins & Morton is a privately-held, innovation-driven construction firm committed to Building with Purpose®. Since 1946, the firm has built a reputation as a trusted advisor to clients nationwide by cultivating a high-performing team that values integrity, safety, and innovative thinking. Robins & Morton consistently ranks among the Top 100 U.S. Builders in Engineering News-Record. Robins & Morton is based in Birmingham, Alabama, with additional offices in Charlotte, North Carolina; Dallas, Texas; Huntsville, Alabama; Miami and Orlando, Florida; Nashville, Tennessee. Learn more at http://www.robinsmorton.com.

Share article on social media or email:

“We are another step closer to having the first FDA approved therapy for peanut allergy; this is truly a groundbreaking development. Patients and their families have been waiting for this for many years and will be eagerly awaiting the FDA’s final decision.” – David M. Lang, MD, FAAAAI

MILWAUKEE (PRWEB)
September 13, 2019

The Allergenic Products Advisory Committee of the Food and Drug Administration (FDA) met today and voted, based on the available safety and efficacy data, to recommend approval of a standardized oral immunotherapy (OIT) product for peanut allergy. The brand name is expected to be Palforzia, but it was previously referred to as AR101.

The FDA would require a Risk Evaluation and Mitigation Strategy (REMS) to be developed to help ensure the benefits of Palforzia outweigh the risks, and to put additional safeguards in place for patients. The REMS would be in addition to a “black box” warning, the FDA’s most stringent label, in the prescribing information.

While the FDA still needs to complete its review of the product and announce a final decision, the American Academy of Allergy, Asthma & Immunology (AAAAI) seeks to share important information about OIT to help patients and families understand the current state of this therapy.

“This is the first potential treatment for any type of food allergy to be recommended for FDA approval,” said AAAAI President David M. Lang, MD, FAAAAI, who is also Chair of the Allergy/Immunology Department in the Respiratory Institute at Cleveland Clinic. “After today’s meeting, we are another step closer to having the first FDA approved therapy for peanut allergy; this is truly a groundbreaking development. Patients and their families have been waiting for this for many years and will be eagerly awaiting the FDA’s final decision.”

As everyone awaits the FDA’s final decision, here are some factors peanut allergic patients and their families should be aware of when considering OIT:

How OIT Works

OIT refers to feeding an allergic individual an increasing amount of an allergen with the goal of increasing the threshold that triggers a reaction.

For example, Palforzia or AR101 is a capsule filled with peanut powder and can be mixed into food. By taking it, patients are exposed to controlled doses of peanut protein, with the dose gradually increasing over time. Ideally the higher doses will eventually induce a level of tolerance sufficient to prevent severe allergic reactions after accidental exposure to peanut.

A Treatment, Not a Cure

OIT is not a cure. It is likely that most allergic patients receiving OIT must remain on it indefinitely, and patients must continue to avoid dietary exposure to the allergen and continue carrying auto-injectable epinephrine.

Shared Decision Making between Patients, Families and Physicians is Crucial

OIT will not be right for every patient. It is not a “one size fits all” approach. How to predict which individuals will respond to OIT and which individuals will be at highest risk of side effects has not been clearly determined, and there are many other important questions about OIT that require ongoing study.

The AAAAI encourages patients and families to engage with an allergist/immunologist to discuss the risks, benefits, and alternatives of OIT and all other emerging treatments for food allergy. Ultimately, the choice of treatment, including that of active non-intervention, will be based on individual and family factors after careful discussion with one’s physician.

“Patients and their families will need to understand the realities of these new therapies. As physicians, we must invest the time to explain the potential for benefit compared with the potential for harm/burden, and permit patients and families to express their values and preferences, allowing them to participate in the medical decision making process to determine whether they desire to proceed with food oral immunotherapy,” said Dr. Lang.

Learn more about the current state of oral immunotherapy at the AAAAI’s website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has nearly 7,000 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

Share article on social media or email: